drugset / Trial / NCT02545127

Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely

NCT02545127 ↗

Phase 2 Terminated 4 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

Induction and support of lactation in women with preterm delivery and inadequate milk production.

Timeline

Start
2021-05-28
Primary completion
2022-11-11
Completion
2022-11-11

Outcome

Outcome not reported

Stopped (Enrollment): “The trial was prematurely terminated. Termination was not because of safety concerns but due to slow recruitment.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Merotocin Unknown 400 ug Intranasal

Indications

No indication recorded.